论文部分内容阅读
目的观察了解多西紫杉醇联合吉西他滨治疗晚期非小细胞肺癌(NSCLC)的临床疗效和毒性反应。方法42例Ⅲ～Ⅳ期NSCLC患者均经病理组织学和(或)细胞学检查确诊。多西紫杉醇联合吉西他滨治疗后评价疗效。结果42例患者均可评价,获得CR3例,PR16例,有效率45.2%(19/42)。最主要的毒副反应为白细胞及血小板降低,但均可耐受。生存质量较前改善。结论西紫杉醇联合吉西他滨治疗晚期NSCLC有较好疗效,可明显改善患者生存质量,,毒副反应轻,易于耐受。
Objective To investigate the clinical efficacy and toxicity of docetaxel combined with gemcitabine in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 42 cases of stage Ⅲ ~ Ⅳ NSCLC patients were confirmed by histopathology and / or cytology. Docetaxel and gemcitabine after treatment evaluation. Results All the 42 patients were evaluable. CR3 and PR16 cases were obtained. The effective rate was 45.2% (19/42). The main side effects of leukopenia and thrombocytopenia, but can be tolerated. Quality of life improved earlier. Conclusion West-paclitaxel combined with gemcitabine in the treatment of advanced NSCLC has a good curative effect, which can significantly improve the quality of life of patients with less toxic side effects and is easily tolerated.